{"nctId":"NCT00490139","briefTitle":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","startDateStruct":{"date":"2007-05-16","type":"ACTUAL"},"conditions":["Neoplasms, Breast"],"count":8381,"armGroups":[{"label":"Lapatinib plus Trastuzumab","type":"EXPERIMENTAL","interventionNames":["Drug: Lapatinib","Biological: Trastuzumab"]},{"label":"Trastuzumab followed by Lapatinib","type":"EXPERIMENTAL","interventionNames":["Drug: Lapatinib","Biological: Trastuzumab"]},{"label":"Lapatinib","type":"EXPERIMENTAL","interventionNames":["Drug: Lapatinib"]},{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Trastuzumab"]}],"interventions":[{"name":"Lapatinib","otherNames":["GW572016"]},{"name":"Trastuzumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Patients \\>= 18 years of age with histologically confirmed, non-metastatic, operable and over expression/amplification of HER2 (3+ by IHC and/or FISH positive) primary breast cancer, treated with definitive surgery, with baseline LVEF \\>= 50%, known hormone receptor status (ER/PgR or ER alone) and ECOG performance status =\\< 1, were included.\n* For Designs 1 and 2: Patients must have had received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen or a protocol specified exception.\n* Approved, signed written informed consent obtained prior to any study specific screening procedures.\n\nKey Exclusion Criteria:\n\n* History of any prior (ipsi- and/or contralateral) invasive breast carcinoma, past (less than 10 years) or current history of malignant neoplasms, any clinically staged T4 tumor, or bilateral tumors.\n* Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;\n* Patients with positive or suspicious internal mammary nodes identified by sentinel node technique, which had not been irradiated or would not be irradiated, or patients with supraclavicular lymph node involvement.\n* Any prior anti-HER therapy, which includes agents that target other members of the HER family of receptors, e.g. gefitinib (Iressa)\n* (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;\n* Serious cardiac illness or medical conditions.\n* Any of the following abnormal laboratory tests immediately prior to randomization:\n\n  1. Serum total bilirubin \\>1.5 x upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\\<2 x ULN) was allowed;\n  2. Alanine amino transferase (ALT) or aspartate amino transferase (AST) \\>2.5 x ULN;\n  3. Alkaline phosphatase (ALP) \\>2.5 x ULN;\n  4. Serum creatinine \\>2.0 x ULN;\n  5. Total white blood cell count (WBC) \\<2.5 x 10\\^9/L;\n  6. Absolute neutrophil count \\<1.5 x 10\\^9/L;\n  7. Platelets \\<100 x 10\\^9/L.\n* Women of childbearing potential and male patients with partners of childbearing potential, who are unable or unwilling to use adequate contraceptive measures during study treatment, and pregnant or lactating women.\n* Concomitant use of CYP3A4 inhibitors or inducers.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-Free Survival (DFS) at the Primary Analysis","description":"Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"1.8","spread":null},{"groupId":"OG003","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival (DFS) at the 10-Year Follow-Up","description":"Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who had disease free survival for the indicated years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":null},{"groupId":"OG001","value":"1.27","spread":null},{"groupId":"OG003","value":"1.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","spread":null},{"groupId":"OG001","value":"2.80","spread":null},{"groupId":"OG003","value":"2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":null},{"groupId":"OG001","value":"4.85","spread":null},{"groupId":"OG003","value":"4.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","spread":null},{"groupId":"OG001","value":"9.18","spread":null},{"groupId":"OG003","value":"7.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) at the Primary Analysis","description":"Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG003","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG003","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"2.9","spread":null},{"groupId":"OG003","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG003","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG003","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) at the 10-Year Follow-Up","description":"Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 95 and 90 percent) of participants who survived for the indicated years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":null},{"groupId":"OG001","value":"1.17","spread":null},{"groupId":"OG003","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":null},{"groupId":"OG001","value":"1.60","spread":null},{"groupId":"OG003","value":"2.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":null},{"groupId":"OG001","value":"3.52","spread":null},{"groupId":"OG003","value":"3.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.31","spread":null},{"groupId":"OG001","value":"8.49","spread":null},{"groupId":"OG003","value":"6.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Analysis of Time to Recurrence (TTR)","description":"Time to Recurrence (TTR) was defined as the the time from randomization to breast cancer recurrence, ignoring second primary cancers (including contralateral breast cancers and non-breast second malignancies) and counting deaths without recurrence as a competing risk.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"275","spread":null},{"groupId":"OG003","value":"298","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG003","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1807","spread":null},{"groupId":"OG001","value":"1778","spread":null},{"groupId":"OG003","value":"1753","spread":null}]}]}]},{"type":"SECONDARY","title":"Analysis of Time to Distant Recurrence (TTDR)","description":"Time to Distant Recurrence (TTDR) was defined as the the time from randomization to first distant breast cancer recurrence, ignoring locoregional recurrences and second primary cancers, (including contralateral breast cancers and non-breast second malignancies ) and counting deaths without recurrence as a competing risk.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG003","value":"250","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG003","value":"54","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1835","spread":null},{"groupId":"OG001","value":"1812","spread":null},{"groupId":"OG003","value":"1793","spread":null}]}]}]},{"type":"SECONDARY","title":"Analysis of Time to Central Nervous System (CNS) Recurrence","description":"Time to Central Nervous System (CNS) recurrence was defined as the time from randomization to first CNS recurrence. Both brain metastasis and meningitis carcinomatosa were considered.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG003","value":"95","spread":null}]},{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"117","spread":null},{"groupId":"OG003","value":"142","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1888","spread":null},{"groupId":"OG001","value":"1883","spread":null},{"groupId":"OG003","value":"1860","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Brain Metastases","description":"The cumulative incidence of brain metastases as the first site of breast cancer recurrence among treatment arms was assessed using a hierarchy of primary type and location of first DFS event in cases where more than one event was identified simultaneously. Because diagnostic procedures for different types of recurrence could not be performed on exactly the same day, any diagnoses noted within a two month (60 day) period of the first reported event was considered as identified simultaneously for purposes of defining the type of the first event and the date of event was be regarded as the earliest of the relevant events.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.\n\nOn-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 56 weeks.\n\nDeaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 10 years.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"190","spread":null},{"groupId":"OG002","value":"250","spread":null},{"groupId":"OG003","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"263","spread":null},{"groupId":"OG003","value":"233","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":379,"n":2061},"commonTop":["DIARRHOEA","RASH","FATIGUE","ARTHRALGIA","NAUSEA"]}}}